Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

0.1913 UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1913
Bid (Size) 0.1900 (4)
Ask (Size) 0.1901 (279)
Prev. Close 0.1913
Today's Range 0.1913 - 0.1913
52wk Range 0.1913 - 3.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
From NKGen Biotech
Via GlobeNewswire

Performance

YTD
-72.32%
-72.32%
1 Month
-49.11%
-49.11%
3 Month
-63.28%
-63.28%
6 Month
-75.47%
-75.47%
1 Year
-88.94%
-88.94%

More News

Read More
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
From NKGen Biotech
Via GlobeNewswire
Wondering what's happening in today's pre-market session?
Via Chartmill
These stocks are the most active in today's session
Via Chartmill
Gapping stocks in Friday's session
Via Chartmill
These stocks are moving in today's pre-market session
Via Chartmill
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
From NKGen Biotech
Via GlobeNewswire
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
From NKGen Biotech
Via GlobeNewswire
Top movers in Friday's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill
Which stocks are moving on Thursday?
Via Chartmill
Thursday's session: gap up and gap down stocks
Via Chartmill
Thursday's pre-market session: top gainers and losers
Via Chartmill
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Keep an eye on the top gainers and losers in Wednesday's session.
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Wednesday's pre-market session: top gainers and losers
Via Chartmill
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
From NKGen Biotech, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.